Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 10/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | KDM4A | O75164 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14986954 | 0.87 | GLS (0.57) | GLSKDM4ACA12CA1CA7 | |
| SCHEMBL8786913 | 0.87 | GLS (0.57) | GLSKDM4ABRD4CREBBPNAMPT | |
| SCHEMBL28211519 | 0.86 | GLS (0.62) | GLSKDM4ABRD4CREBBP | |
| SCHEMBL16384818 | 0.86 | GLS (0.46) | GLSCA12CA1CA7CA14 | |
| SCHEMBL5729298 | 0.86 | GLS (0.54) | GLSHDAC1KDM4ACA12CA1 | |
| SCHEMBL14987233 | 0.86 | GLS (0.50) | GLSCA1CYP1A2CYP2C19IDO1 | |
| SCHEMBL185365 | 0.86 | ATM (0.55) | GLSHDAC1KDM4ACA12CA1 | |
| SCHEMBL16181822 | 0.85 | GLS (0.55) | GLSHDAC1KDM4ACA12CA1 | |
| SCHEMBL30069429 | 0.85 | GLS (0.55) | GLSHDAC1KDM4ACA12CA1 | |
| SCHEMBL8342682 | 0.85 | GLS (0.55) | GLSHDAC1KDM4ACA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116368131-B | Novel Smad3 protein degradation agent and application thereof | 和径医药科技（上海）有限公司 | 2024-09-20 | — | — | CN | disclosed |
| CN-116368131-A | Novel Smad3 protein degradation agent and application thereof | 和径医药科技（上海）有限公司 | 2023-06-30 | — | — | CN | disclosed |
| CN-116253724-A | Novel Smad3 protein degradation agent and application thereof | 和径医药科技（上海）有限公司 | 2023-06-13 | — | — | CN | disclosed |
| WO-2022148459-A1 | CLASS OF NOVEL SMAD3 PROTEIN DEGRADERS AND APPLICATION THEREOF | 和径医药科技（上海）有限公司 | 2022-07-14 | — | — | WO | disclosed |
| WO-2022148459-A1 | CLASS OF NOVEL SMAD3 PROTEIN DEGRADERS AND APPLICATION THEREOF | 和径医药科技（上海）有限公司 | 2022-07-14 | — | — | WO | disclosed |
| CN-108785305-B | Heterocyclic inhibitors of glutaminase | 卡利泰拉生物科技公司 | 2021-10-29 | — | — | CN | disclosed |
| US-20200165238-A1 | Heterocyclic Inhibitors of Glutaminase | CALITHERA BIOSCIENCES INC. | 2020-05-28 | — | — | US | disclosed |
| US-20200165238-A1 | Heterocyclic Inhibitors of Glutaminase | CALITHERA BIOSCIENCES INC. | 2020-05-28 | — | — | US | disclosed |
| EP-3620162-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | Calithera Biosciences Inc. (US) | 2020-03-11 | — | — | EP | disclosed |
| CN-104220070-B | Heterocyclic inhibitors of glutaminase | 卡利泰拉生物科技公司 | 2020-01-21 | — | — | CN | disclosed |
| US-8604016-B2 | Heterocyclic inhibitors of glutaminase | CALITHERA BIOSCIENCES INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-20130157998-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130157998-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. (US) | 2013-06-20 | — | — | US | disclosed |
| WO-2013078123-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. (US) | 2013-05-30 | — | — | WO | disclosed |
| WO-2010130708-A1 | BETA-LACTAMASE INHIBITORS | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292185-A1 | BETA-LACTAMASE INHIBITORS | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD (BM) | 2010-11-18 | — | — | US | disclosed |
| EP-0386839-B1 | Tetrahydroquinoline derivatives useful for neurodegenerative disorders | MERCK SHARP & DOHME (GB) | 1997-01-15 | — | — | EP | disclosed |
| US-5231102-A | Tetrahydroquinoline derivatives useful for neurodegenerative disorders | MERCK SHARP & DOHME, LTD. (GB) | 1993-07-27 | — | — | US | disclosed |
| EP-0386839-A2 | Tetrahydroquinoline derivatives useful for neurodegenerative disorders | MERCK SHARP & DOHME LTD. (GB) | 1990-09-12 | — | — | EP | disclosed |
| US-4159373-A | 7-Acyl-3-(sulfonic acid and sulfamoyl substituted tetrazolyl thiomethyl) cephalosporins | SMITHKLINE CORPORATION (US) | 1979-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200165238-A1 | Heterocyclic Inhibitors of Glutaminase | GLS, GLS2, GLUL | GLS 1/4885HDAC1 1329/4885KDM4A 954/4885 |
| US-20100292185-A1 | BETA-LACTAMASE INHIBITORS | GANAB, BPGM, BLVRB | GLS 422/4885HDAC1 3077/4885KDM4A 2446/4885 |
| US-20130157998-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | GLS 1/4885HDAC1 1329/4885KDM4A 954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.